Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia: Current and Emerging Treatments

Author： Martin Alissa   Morgan Elaine   Hijiya Nobuko  

Publisher： Adis International

ISSN： 1174-5878

Source： Pediatric Drugs, Vol.14, Iss.6, 2012-12, pp. : 377-387

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging Treatments in Acute Lymphoblastic Leukemia

By  

Current Cancer Drug Targets, Vol. 9, Iss. 1, 2009-02 ,pp. : 19-31

Bentham Science Publishers

Access to resources Recommend Favorite

Imatinib: In Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

By Cross Sarah A.   Lyseng-Williamson Katherine A.  

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2645-2654

Adis International

Access to resources Recommend Favorite

Clofarabine: In Pediatric Patients with Acute Lymphoblastic Leukemia

By Curran Monique P.   Perry Caroline M.  

Pediatric Drugs, Vol. 7, Iss. 4, 2005-01 ,pp. : 259-264

Adis International

Access to resources Recommend Favorite

Novel and Emerging Drugs for Acute Lymphoblastic Leukemia

By  

Current Cancer Drug Targets, Vol. 12, Iss. 5, 2012-05 ,pp. : 505-521

Bentham Science Publishers

Access to resources Recommend Favorite

Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives

By  

Current Medicinal Chemistry, Vol. 24, Iss. 11, 2017-05 ,pp. : 1050-1065

Bentham Science Publishers

Access to resources Recommend Favorite